A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFudan University
About this trial
This study is a multicenter, registered research aimed at evaluating the efficacy of different treatment regimens in the treatment of unresectable CNLC liver cancer stage III hepatocellular carcinoma
Eligibility criteria
Qualifiers
Diagnosed as unresectable hepatocellular carcinoma through histopathological and/or cytological examination, or meeting the clinical diagnostic criteria for hepatocellular carcinoma in the 2022 edition of the guidelines for the diagnosis and treatment of primary liver cancer;
CNLC liver cancer stage III;
Liver function Child Pugh A or B grade 7 points;
Has not received systematic treatment in the past;
Disqualifiers
Simultaneously having two or more active primary malignant tumors;
Portal vein cancer thrombus invades the superior mesenteric vein;
Received radiation therapy within the past 4 weeks;
Expected survival time is less than 3 months;
Trial design
Treatments tested in this trial
- Targeted drugs combined with anti-PD-1/PD-L1 antibodies
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Lenvatinib monotherapy
- Huaier granules combined with any of the above Cohorts for treatment
Treatment groups
750 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Fudan University
Lead sponsor
LinkDoc Technology (Beijing) Co. Ltd.
Collaborator
Huazhong University of Science and Technology
Collaborator
Source ClinicalTrials.gov